Myriad Genetics Announces Global Expansion of Myriad myChoice® Tumor Testing in Europe and China
SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China.
- SALT LAKE CITY, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics and precision medicine, announced today the expansion of Myriad myChoice tumor testing in several European markets and China.
- As part of the expansion in Europe, Myriad will license and provide technological support to leading pathology institutes in Germany and France.
- Additionally, Myriad will support European customers by performing testing out of its clinical laboratory at the companys global headquarters in Salt Lake City.
- Also, the institutes in Europe will perform the tests with Myriads myChoice CDx PLUS assay.